M S Kramer

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Distinct mechanism for antidepressant activity by blockade of central substance P receptors
    M S Kramer
    Merck Research Laboratories, West Point, PA 19456, USA
    Science 281:1640-5. 1998
  2. ncbi request reprint Improvement in migraine-specific quality of life in a clinical trial of rizatriptan
    N C Santanello
    Merck and Co, Inc, West Point, PA 19486, USA
    Cephalalgia 17:867-72; discussion 800. 1997
  3. ncbi request reprint Novel strategies for pharmacotherapy of depression
    K A Maubach
    Merck Sharp and Dohme Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
    Curr Opin Chem Biol 3:481-8. 1999
  4. ncbi request reprint Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
    N M Rupniak
    Merck Sharp and Dohme Neuroscience Research Centre, Harlow, Essex, UK
    Trends Pharmacol Sci 20:485-90. 1999

Detail Information

Publications4

  1. ncbi request reprint Distinct mechanism for antidepressant activity by blockade of central substance P receptors
    M S Kramer
    Merck Research Laboratories, West Point, PA 19456, USA
    Science 281:1640-5. 1998
    ..These findings suggest that substance P may play an important role in psychiatric disorders...
  2. ncbi request reprint Improvement in migraine-specific quality of life in a clinical trial of rizatriptan
    N C Santanello
    Merck and Co, Inc, West Point, PA 19486, USA
    Cephalalgia 17:867-72; discussion 800. 1997
    ..The O'Brien's Rank Sum Test statistic showed a statistically significant overall difference on the 24-h MQoLQ between the 10 mg rizatriptan and placebo groups (p=0.005) and for the overall dose trend (p< or =0.001)...
  3. ncbi request reprint Novel strategies for pharmacotherapy of depression
    K A Maubach
    Merck Sharp and Dohme Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
    Curr Opin Chem Biol 3:481-8. 1999
    ..Efforts in this area have recently been rewarded by the demonstration of antidepressant efficacy of the substance P receptor antagonist MK-0869...
  4. ncbi request reprint Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
    N M Rupniak
    Merck Sharp and Dohme Neuroscience Research Centre, Harlow, Essex, UK
    Trends Pharmacol Sci 20:485-90. 1999
    ..Thus, multiple clinical trials, targeted to appropriate patient populations, are necessary to define the therapeutic potential of novel neurotransmitter ligands...